Using Lifei Xiaoji Wan to treat advanced lung cancer
Clinical Efficacy of Lifei Xiaoji Wan in Treatment of Advanced NSCLC
This study is testing whether Lifei Xiaoji Wan can help people with advanced lung cancer live longer and feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Henan University of Traditional Chinese Medicine Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT06406166 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Lifei Xiaoji Wan in treating patients with advanced non-small cell lung cancer (NSCLC). It aims to establish a treatment scheme and gather high-quality clinical evidence through a multicenter randomized controlled trial. The study will assess overall survival, progression-free survival, and quality of life measures, while also investigating the safety and potential mechanisms of action of Lifei Xiaoji Wan. Previous animal studies suggest that this treatment may inhibit tumor growth and cancer cell proliferation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with a clinical diagnosis of advanced NSCLC (stage III to IV) and an expected survival of more than 3 months.
Not a fit: Patients with early-stage NSCLC, serious organ dysfunction, or mental illness may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced NSCLC.
How similar studies have performed: While traditional Chinese medicine approaches have been explored, this specific evaluation of Lifei Xiaoji Wan in advanced NSCLC is novel and lacks prior high-level clinical evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical diagnosis of NSCLC. 2. The tumor stage (TNM) stage is from III to IV. 3. 18-80 years old. 4. The expected survival period is\> 3 months. Exclusion Criteria: 1. Early-stage patients with prior surgery and no recurrence. 2. Patients with serious dysfunction of the heart, liver, heart, kidney, and other important organs. 3. Mental illness and other patients were unable to complete the study.
Where this trial is running
Zhengzhou, Henan
- the First Affiliated Hospital of Henan University of Chinese Medicine — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Yuanyuan Wang, MD
- Email: 40685685@qq.com
- Phone: 0371-66248624
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.